Author/Editor		Mencej Bedrač, Simona; Zupan, Janja; Kocjan, Tomaž; Mlakar, Vid; Preželj, Janez; Marc, Janja; Ostanek, Barbara
Title		Zdravljenje osteoporoze danes in jutri
Translated title		Treatment of osteoporosis now and in the future
Type		članek
Source		Farm Vestn
Vol. and No.		Letnik 63, št. 5-6
Publication year		2012
Volume		str. 279-89
Language		slo
Abstract		In developed countries, 75 million individuals suffer from osteoporosis. Everyyear, more that 2,3 million osteoporotic fractures occur in Europe and USA. In Slovenia, osteoporosis affects 27.5% of women after the age of 50, and 14.6% of men after the age of 60. For prevention of osteoporotic fractures,bisphosphonates, selective estrogen receptor modulators (SERMs) and strontium ranelate are used. Since 2010, the first human monoclonal antibody denosumab is available for treatment of osteoporosis. Teriparatide is an osteoanabolic drug which is used due to its high price only in patients with new osteoporotic fracture occuring during other osteoporosis treatment. At the moment, numerous new medicines for the treatment of osteoporosis are being tested. The most promising seem to be cathepsine K inhibitors and substances, targeting Wnt signalling pathway. We believe that new medicines will enable a selection of a more appropriate treatment for a specific patient and will therefore markedly reduce the number of osteoporotic fractures.
Summary		V razvitem svetu ima osteoporozo več kot 75 miljonov ljudi, letno pa se v Evropi in ZDA zgodi več kot 2,3 miljona osteoporoznih zlomov. V Sloveniji je prevalenca osteoporoze pri ženskah po 50. letu 27,5 %, pri moških po 60. letu pa 14,6 %. Za preprečevanje osteoporoznih zlomov lahko uporabimo difosfonate, selektivne modulatorje estrogenskih receptorjev (SERM) in stroncijev ranelat, od leta 2010 pa tudi prvo biološko zdravilo, denosumab. Teriparatid je osteoanabolno zdravilo, ki ga zaradi visoke cene uporabljamo le, če pride do novega zloma med zdravljenjem z drugimi zdravili. V različnih fazah raziskav so številna nova zdravila za zdravljenje osteoporoze. Največ obetajo zaviralci katepsina K in molekule, ki delujejo na signalno pot Wnt. Verjamemo, da bodo nova zdravila omogočila boljšo izbiro pravega načina zdravljenja za posameznega bolnika in tako pomembno zmanjšala število osteoporoznih zlomov.